Biology, Diagnosis and Treatment, Epidemiology and Prevention
Participatory Learning and Action Planning; A Facilitator's Guide
This research is one case in a study commissioned by the World Food Programme to investigate the participation of recipient community in the targeting and management of humanitarian food assistance in complex emergencies. The study involved a substantial desk review of existing documentation, and th...ree weeks of field work in February and March 2008. The purpose of the study was to understand the ways in which participatory or community-based approaches to targeting have been attempted, within the definition of community-based targeting suggested by WFP. The study was not an evaluation of targeting methods, although some critical examination of targeting was necessary in order to understand the constraints on community participation.
Related resources
more
Guidelines for Prevention and Reponse
Plan de mejora de la calidad de atencíon y seguridad de los pacientes
Tobacco control legislation: an introductory guide
Joint WHO/ILO guidelines on post-exposure prophylaxis (PEP) to prevent HIV infection.
La silla de ruedas es uno de los medios de asistencia de uso más frecuente para mejorar la movilidad personal, condición previa para disfrutar de los derechos humanos y una vida digna, y ayuda a las personas con discapacidad a convertirse en miembros más productivos de sus comunidades. Para mucho...s, una silla de ruedas adecuada, bien diseñada y armada puede constituir el primer paso hacia la inclusión y participación en la sociedad.
Este documento ha sido publicado con el fin de ayudar a los Estados Miembros de la OMS a crear y desarrollar un sistema local de suministro de sillas de ruedas y poner así en ejecución los Artículos 4, 20 y 26 de la Convención sobre los Derechos de las Personas con discapacidad.
more
In 2015, the United Nations set important targets to reduce premature
cardiovascular disease (CVD) deaths by 33% by 2030. Africa disproportionately
bears the brunt of CVD burden and has one of the highest risks of dying
from non-communicable diseases (NCDs) worldwide. There is currently
an epide...miological transition on the continent, where NCDs is projected
to outpace communicable diseases within the current decade. Unchecked
increases in CVD risk factors have contributed to the growing burden of three
major CVDs—hypertension, cardiomyopathies, and atherosclerotic diseasesleading to devastating rates of stroke and heart failure. The highest age
standardized disability-adjusted life years (DALYs) due to hypertensive heart
disease (HHD) were recorded in Africa. The contributory causes of heart failure
are changing—whilst HHD and cardiomyopathies still dominate, ischemic
heart disease is rapidly becoming a significant contributor, whilst rheumatic
heart disease (RHD) has shown a gradual decline. In a continent where health
systems are traditionally geared toward addressing communicable diseases,
several gaps exist to adequately meet the growing demand imposed by CVDs.
Among these, high-quality research to inform interventions, underfunded
health systems with high out-of-pocket costs, limited accessibility and
affordability of essential medicines, CVD preventive services, and skill
shortages. Overall, the African continent progress toward a third reduction
in premature mortality come 2030 is lagging behind. More can be done in
the arena of effective policy implementation for risk factor reduction and
CVD prevention, increasing health financing and focusing on strengthening
primary health care services for prevention and treatment of CVDs, whilst
ensuring availability and affordability of quality medicines. Further, investing
in systematic country data collection and research outputs will improve the accuracy of the burden of disease data and inform policy adoption on
interventions. This review summarizes the current CVD burden, important
gaps in cardiovascular medicine in Africa, and further highlights priority
areas where efforts could be intensified in the next decade with potential
to improve the current rate of progress toward achieving a 33% reduction
in CVD mortality.
more